Autopsy report · NCT04025632

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study was terminated based on the primary efficacy endpoint analysis after the first data lock.”

The sponsor’s own words in the registry.

Life of this trial

Registered 4 months before it started.
Ran for about 1 year 7 months before it stopped.
27 participants enrolled.
Results were posted on the registry 11 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Ra Pharmaceuticals
Sponsor type: Industry
Conditions: Immune Mediated Necrotizing Myopathy
Interventions: zilucoplan; Placebo
Participants: 27
Sites: 18
Countries: France, Netherlands, United Kingdom, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.